Tag: Upgrade

T-Mobile bullish on analyst upgrade today

TMUS – T-Mobile US Inc provides mobile communications services to consumers and businesses.

TMUS – T-Mobile US, Inc

Fundamentals Previously closed at 45.96
Day’s high 47.18
Day’s low 46.50
P/E ratio

­

36.06

 

Analysts opinion Wells Fargo upgraded TMUS to “Outperform” from “Market Perform”. The price target range was also raised to $52 – $54 from $48 – $50. According to the Fly, Wells Fargo said that the company’s cash-flow would ramp up significantly in 2017. Analyst confidence meter, a proprietary algorithm of Stockal gives 72% buy based on analyst ratings.
Sentiments The sentiment index is 50% positive according to Stockal proprietary algorithm.
Social Media Pulse The stock has 33% lower social media chatter than usual.

 

Disclaimer: This blog contains an aggregated view of analysts and opinions by the author. Do not consider this as financial advice. See http://stockal.com/legalities/

A brief analysis of Zafgen and HP Inc

ZFGN – Zafgen, Inc is a bio-pharmaceutical company, engaged in developing medicines for patients affected by obesity and complex metabolic disorders. Analysts have a positive outlook for the stock.

ZFGN – Zafgen, Inc

Fundamentals Previously closed at 6.70
Day’s high 6.86
Day’s low 6.49
P/E ratio NA
EPS -2.77

 

Analysts opinion Zafgen has been given a “Buy” rating by analysts, with a target price of $17. It previously reported an EPS of -$1.85.  It announced today that it has achieved its primary efficacy points in the phase 3 trial for evaluating Beloranib – a subcutaneous injection, developed for treatment of multiple indications including severe obesity in two rare cases. This news has driven the stock up by 11% pre-market.
Insider James. E. Flynn is reported to have bought 64,545 shares of the firm at an average of $6.25 per share on February 12th this year. Also, an institutional investor, Janus Capital Management increased their stake in Zafgen.
Sentiments Beloranib could be the only potential cure for PWS, which affects one in 12000-15000 people. Despite being considered a rare disorder, PWS is the most common condition seen in genetic clinics.  The sentiments for ZFGN may rise further in the short term, and would depend on FDA approval in the near future.
Social Media Pulse The stock has 72% higher chatter than usual.

Continue Reading…

Bullish sentiments for Ardelyx, Inc and Target Corporation

ARDX– Ardelyx, Inc is a clinical stage bio-pharmaceutical company which develops therapeutic drugs for the treatment of Gastro-Intestinal and Cardio – Renal diseases. ARDX was given a “Buy”rating from Ladenburg Thalmann, and may be bullish today.

ARDX – Ardelyx, Inc.

Fundamentals Previously closed at 7.77
Day’s high 8.02
Day’s low 7.41
P/E ratio NA
EPS -0.76

 

Analysts opinion Out of the 4 wall street analysts covering the stock, all 4 have given this stock a “Strong Buy” rating. For the most recent quarter, Ardelyx reported a surprise factor of 12.16%. The Analyst consensus price target for the stock is $19.
Anapanor, Ardelyx’s lead investigational drug expected to cure IBS-C (Irritable bowel syndrome with constipation) is currently under Phase 3 clinical studies. According to study, there are approx. 4.4 million Americans, 6.6 million Europeans, and 3.4 Japanese suffering from IBS-C- a huge potential market for Anapanor.
Sentiments One of Ardelyx’s Director Gordon Ringold purchased 15,000 shares of the firm at $7.64 – $7.86 per share. This may cause further bullish investor sentiments
Social Media Pulse The stock has 100% lower chatter than usual.

Continue Reading…